Transfusion-transmitted infection in hemophilia in developing countries

Seminars in Thrombosis and Hemostasis

Volumn 31, Issue 5, 2005, Pages 527-537

  Yee, Thynn Thynn ^a   Lee, Christine A ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Antiretroviral treatment; Developing countries; Factor concentrates; HBV; HCV; Hemophilia; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; BLOOD CLOTTING FACTOR CONCENTRATE; FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9;

BLOOD COMPONENT THERAPY; BLOOD DONOR; BLOOD TRANSFUSION; CRYOPRECIPITATE; DEVELOPING COUNTRY; DRUG SAFETY; HEMOPHILIA; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; VIRUS INACTIVATION; VIRUS TRANSMISSION;

BLOOD COAGULATION FACTORS; BLOOD COMPONENT TRANSFUSION; DEVELOPING COUNTRIES; HEMOPHILIA A; HUMANS; VIRUS DISEASES; VIRUS INACTIVATION;

EID: 27844550759     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-922224     Document Type: Review

References (60)

1. Lee CA, Phillips A, Elford J, et al. The natural history of human immunodeficiency virus infection in a haemophilic cohort. Br J Haematol 1989;73:228-234
2. Kernoff PB, Lee CA, Karayiannis P, Thomas HC. High risk of a non-A non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates effects of prophylactic immune serum globulin. Br J Haematol 1985;60:469-479
3. The Economist. Could AIDS explode in India? Economist 2004;(April):17
4. Mannucci PM. The choice of plasma-derived clotting factor concentrates. Baillieres Clin Haematol 1996;9:273-290
5. Farrugia A. Safety and supply of haemophilia products: worldwide perspectives. Haemophilia 2004;10:327-333
6. Yee TT, Cohen BJ, Pasi KJ, Lee CA. Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate. Br J Haematol 1996;93:457-459
7. Burnouf T, Radosevich M. Reducing the risk of infection from plasma products; specific preventative strategies. Blood Rev 2000;14:94-110
8. Srivastava A. Factor replacement therapy in haemophilia-are there models for developing countries? Haemophilia 2003;9:391-396
9. Bird A, Isarangkura P, Almagro D, Gonzaga A, Srivastava A. Factor concentrates for haemophiliacs in the developing world. Haemophilia 1998;4:481-485
10. Chuansumrit A. Treatment of haemophilia in the developing countries. Haemophilia 2003;9:387-390
11. Petersen IP, Bird AR. Small pool heat treated intermediate purity factor VIII concentrate. Montreal, Canada: World Federation of Haemophilia Monograph; 1997;(April):1-4
12. WFH Global Survey 2003. World Federation of Haemophilia. Available at: http://www.wfh.org. Accessed August 5, 2005
13. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a C DNA done derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-362
14. Rosenberg W, Khakoo S. Epidemiology, natural history and pathophysiology. In: Pocket Reference to Hepatitis C Infection. London: Science Press; 2002
15. Mansour-Ghanaei F, Fallah MS, Shafaghi A, et al. Prevalence of hepatitis B and C seromarkers and abnormal liver function tests among hemophiliacs in Guilan (northern province of Iran). Med Sci Monit 2002;8:797-800
16. Timan IS, Aulia D, Atmakusma D, et al. Some hematological problems in Indonesia. Int J Hematol 2002;76(suppl 1):286-290
17. Seme K, Poljak M, Begovac J, et al. Low prevalence of hepatitis C virus infection among human immunodeficiency virus type 1-infected individuals from Slovenia and Croatia. Acta Virol 2002;46:91-94
18. Wharfe G, Smikle M, Dowe G, et al. Seroprevalence of hepatitis C virus in haemophiliacs in Jamacia. Hum Antibodies 2002;11:61-64
19. Fontes EM, Amorim L, Carvalho SM, Farah MB. Hemophilia care in the state of Rio de Janeiro, Brazil. Rev Panam Salud Publica 2003;13:124-128
20. Carmo RA, Oliveira GC, Guimaraes MD, et al. Hepatitis C virus infection among Brazilian hemophiliacs: a virological, clinical and epidemiological study. Braz J Med Biol Res 2002; 35:589-598
21. Barbosa AP, Martins RM, Teles SA, et al. Prevalence of hepatitis C virus infection among hemophiliacs central Brazil. Mem Inst Oswaldo Cruz 2002;97:643-644; errata August 30, 2002
22. Jarvis LM, Watson HG, McOmish F, et al. Frequent reinfection and reactivation of hepatitis C virus genotypes in multitransfused hemophiliacs. J Infect Dis 1994;170:1018-1022
23. Jarvis LM, Ludlam CA, Simmonds P. Hepatitis C virus genotypes in multi-transfused individuals. Haemophilia 1995; 1(suppl 4):3-7
24. Eyster ME, Sherman KE, Goedert JJ, Katsoulidou A, Hatzakis A. Prevalence and changes in hepatitis C virus genotype among multitransfused persons with hemophilia. The Multicenter Hemophilia Cohort Study. J Infect Dis 1999;179:1062-1069
25. Sheng L, Willems M, Peenlinck K, Vermylen J, Yap SH. Hepatitis C virus genotypes in Belgian haemophiliacs. J Med Virol 1995;45:211-214
26. Suou T, Kawatani T, Nishikawa K, et al. High prevalence of hepatitis C virus genotype 1a in Japanese hemophiliacs. Int Hepatol Commun 1996;4:301-304
27. Mauser-Bunschoten EP, Bresters D, Van Drimmelen AA, et al. Hepatitis C infection and viremia in Dutch hemophilia patients. J Med Virol 1995;45:241-246
28. Yee TT, Griffoen A, Sabin CA, Dusheiko G, Lee CA. The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Gut 2000;47:845-851
29. Franchini M, Rossetti G, Tagliferri A, et al. The natural history of chronic hepatitis C in a cohort of HIV negative Italian patients with hereditary bleeding disorders. Blood 2001;98:1836-1841
30. Darby SC, Ewart DW, Giangrande PLF, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in the UK given blood products contaminated with hepatitis C. Lancet 1997;350:1425-1431
31. Wilde JT. HIV and HCV coinfection in haemophilia. Haemophilia 2004;10:1-8
32. Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with haemophilia and hepatitis C virus infection. J Infect Dis 2001;183:1112-1115
33. Quintana M, Villar A, Jimenez V, et al. Progression of HIV infection and mortality by hepatitis infection in patients with haemophilia over 20 years. Haemophilia 2003;9:605-612
34. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in haemphiliacs: relationship to human immunodefiency virus infection and liver disease. Blood 1994;84:1020-1023
35. Fauci AS, Schnittman SM, Poli G, Koenig S, Pantaleo G. Immunopathogenetic mechanisms in human immunodeficiency virus (HIV) infection. Ann Intern Med 1991;114:678-693
36. Sabin CA, Telfer P, Phillips AN, Bhagani S, Lee CA. The association between hepatitis C virus genotype and human immuno-deficiency virus disease progression in a cohort of haemophilic men. J Infect Dis 1997;175:164-168
37. Centers for Disease Control. Pneumocystis carinii pneumonia among persons with haemophilia. MMWR 1982;31:365
38. Bottiger B, Blombäck M, Berntorp E, et al. HIV-serology and Lymphocyte subsets in relation to therapy and clinical development in haemophiliacs. Eur J Haematol 1988;41:459-466
39. Melbye M, Froebel KS, Madhok R, et al. HTLV-III seropositivity in European haemophiliacs receiving factor VIII concentrate imported from the USA. Lancet 1984;2:1444-1446
40. Goedert JJ, Sarngadharan MG, Eyster ME, et al. Antibodies reactive with human T cell leukemia viruses in the serum of haemophiliacs receiving factor VIII concentrate. Blood 1985; 65:492-495
41. Erfle V, Hehlmann R, Mellert W, et al. Prevalence of antibodies to HTLV-III in AIDS risk groups in West Germany. Cancer Res 1985;45(suppl):4627s- 4629s
42. Darby SC, Rizza CR, Doll R, et al. Seropositivity for HIV and incidence of AIDS and AIDS related complex in UK haemophilics: report on behalf of the Directors of haemophilia centres in the UK. BMJ 1989;298:1064-1068
43. Haemophilia Study Group. Haemophilia, HIV infection and blood transfusion in Belgium. Acta Clin Belg 1988;39:44-48
44. Evensen SA, Ulstrup J, Skaug K, et al. HIV infection in Norwegian haemophiliacs treated with lyophilized cryoprecipitate from volunteer donors. Eur J Haematol 1987;39:44-48
45. Rosendaal FR, Smit C, Varekamp I, et al. AIDS and haemophilia: a study among Dutch haemophiliacs on the psychological impact of the AIDS threat, the prevalence of HIV antibodies and the adoption of measures to prevent HIV infection. Haemostasis 1988;18:73-82
46. Rasi V, Ikkala E, Myllyla G, Nevanlinna HR. Low prevalence of antibodies against human immunodeficiency virus in Finnish haemophiliacs. Vox Sang 1991;60:159-161
47. Allain JP. Prevalence of HTLV-III/LAV antibodies in patients with haemophilia and their sexual partners in France. N Engl J Med 1986;315:517-518
48. Singhvi A, Pulimood RB, John TJ, et al. The prevalence of markers for hepatitis B and human immunodeficiency viruses, malarial parasites, and microfilaria in blood donors in a large hospital in south India. J Trop Med Hyg 1990;93:178
49. Karimi M, Yarmohammadi H, Ardeshiri R, Yarmohammadi H. Inherited coagulation disorders in southern Iran. Haemophilia 2002;8:740-744
50. Hosseinipour MC, Kazembe PN, Sanne IM, van der Horst CM. Challenges in delivering antiretroviral treatment in resource poor countries. AIDS 2002;16(suppl 4):S177-187
51. Sherring A, Bergeron M, Mandy F. Comparison of two alternative CD4 T-cell enumerating methods suitable for laboratories with low volume immunophenotyping in resource-poor settings. Program and abstracts of the XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain
52. WHO. Scaling up antiretroviral therapy in resource limited settings: Guidelines for a public health approach: Executive summary. Geneva: World Health Organization; 2002
53. Qazi S, Vareldzis B, Giaquinto C. HIV treatment for children: applying the 2002 WHO interim ARV treatment guidelines for resource poor settings. Program and abstracts or the XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain
54. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002;288:222-235
55. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30
56. Adje C, Cheingsong R, Roels TH, et al. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Lvoire. J Acquir Immune Defic Syndr 2001;26:501-506
57. Vergne L, Malonga-Mouellet G, Mistoul I, et al. Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines in ARV use and HIV-1 drug resistance monitoring in developing countries. J Acquir Immune Defic Syndr 2002;29:165-168
58. James JS. Treatment in developing countries: new UNAIDS pilot program. AIDS Treat News 1997;283:7
59. Weidle PJ, Malamba S, Mwebaze R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients response, survival, and drug resistance. Lancet 2002;360:34-40
60. From Durban to Barcelona. Overcoming the treatment deficit. Available at: http://www.doctorswithoutborders.org/publications/reports/2002/fdtb_07-2002. pdf. Accessed August 5, 2005